Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.

Literature DB >> 23599677

The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.

Abstract

The arrival of ipilimumab and vemurafenib has provided oncologists with new choices in a field in which options were slim and the prognosis was grim. Combination therapy may lead to an improved survival benefit.

Entities: Chemical Disease Gene

Year: 2013 PMID： 23599677 PMCID： PMC3628180

Source DB: PubMed Journal: P T ISSN： 1052-1372

22 in total

Review 1. Guilty as charged: B-RAF is a human oncogene.

Authors: Mathew J Garnett; Richard Marais
Journal: Cancer Cell Date: 2004-10 Impact factor: 31.743

2. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.

Authors: Chris Fellner
Journal: P T Date: 2012-09

3. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.

Authors: James G Greger; Stephen D Eastman; Vivian Zhang; Maureen R Bleam; Ashley M Hughes; Kimberly N Smitheman; Scott H Dickerson; Sylvie G Laquerre; Li Liu; Tona M Gilmer
Journal: Mol Cancer Ther Date: 2012-03-02 Impact factor: 6.261

4. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.

Authors: Nicolas Dumaz; Robert Hayward; Jan Martin; Lesley Ogilvie; Douglas Hedley; John A Curtin; Boris C Bastian; Caroline Springer; Richard Marais
Journal: Cancer Res Date: 2006-10-01 Impact factor: 12.701

5. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

Authors: Timothy R Wilson; Jane Fridlyand; Yibing Yan; Elicia Penuel; Luciana Burton; Emily Chan; Jing Peng; Eva Lin; Yulei Wang; Jeff Sosman; Antoni Ribas; Jiang Li; John Moffat; Daniel P Sutherlin; Hartmut Koeppen; Mark Merchant; Richard Neve; Jeff Settleman
Journal: Nature Date: 2012-07-26 Impact factor: 49.962

6. Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas.

Authors: Roger S Lo
Journal: Pharmacogenomics Date: 2012-01 Impact factor: 2.533

Review 7. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.

Authors: Christophe Frémin; Sylvain Meloche
Journal: J Hematol Oncol Date: 2010-02-11 Impact factor: 17.388

8. Mutations of the BRAF gene in human cancer.

Authors: Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal: Nature Date: 2002-06-09 Impact factor: 49.962

9. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Authors: Ravid Straussman; Teppei Morikawa; Kevin Shee; Michal Barzily-Rokni; Zhi Rong Qian; Jinyan Du; Ashli Davis; Margaret M Mongare; Joshua Gould; Dennie T Frederick; Zachary A Cooper; Paul B Chapman; David B Solit; Antoni Ribas; Roger S Lo; Keith T Flaherty; Shuji Ogino; Jennifer A Wargo; Todd R Golub
Journal: Nature Date: 2012-07-26 Impact factor: 49.962

10. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312

43 in total

1. Cordycepin induces human lung cancer cell apoptosis by inhibiting nitric oxide mediated ERK/Slug signaling pathway.

Authors: Jung Hoo Hwang; Soo Jung Park; Won Gyu Ko; Seong-Mun Kang; Da Bin Lee; Junho Bang; Byung-Joo Park; Chung-Beum Wee; Dae Joon Kim; Ik-Soon Jang; Jae-Hong Ko
Journal: Am J Cancer Res Date: 2017-03-01 Impact factor: 6.166

2. Enhanced antitumor activity and attenuated cardiotoxicity of Epirubicin combined with Paeonol against breast cancer.

Authors: Jing Wu; Xia Xue; Bin Zhang; Hongmei Cao; Feng Kong; Wen Jiang; Juan Li; Deqing Sun; Ruichen Guo
Journal: Tumour Biol Date: 2016-06-07

3. Novel three-dimensional cultures provide insights into thyroid cancer behavior.

Authors: Mason A Lee; Kensey N Bergdorf; Courtney J Phifer; Caroline Y Jones; Sonia Y Byon; Leah M Sawyer; Joshua A Bauer; Vivian L Weiss
Journal: Endocr Relat Cancer Date: 2020-02 Impact factor: 5.678

4. Quantitative Interrogation of the Human Kinome Perturbed by Two BRAF Inhibitors.

Authors: Weili Miao; Yinsheng Wang
Journal: J Proteome Res Date: 2019-04-24 Impact factor: 4.466

5. Microarray gene expression analysis of chemosensitivity for docetaxel, cisplatin and 5-fluorouracil (TPF) combined chemotherapeutic regimen in hypopharyngeal squamous cell carcinoma.

Authors: Meng Lian; Haizhou Wang; Jugao Fang; Jie Zhai; Ru Wang; Xixi Shen; Yifan Yang; Zhihong Ma; Honggang Liu
Journal: Chin J Cancer Res Date: 2017-06 Impact factor: 5.087

6. MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis.

Authors: Huan Liu; Andrew R Osterburg; Jennifer Flury; Zulma Swank; Dennis W McGraw; Nishant Gupta; Kathryn A Wikenheiser-Brokamp; Ashish Kumar; Abdellatif Tazi; Yoshikazu Inoue; Masaki Hirose; Francis X McCormack; Michael T Borchers
Journal: JCI Insight Date: 2020-02-27

10. Clinical Characteristics of BRAF V600E Gene Mutation in Patients of Epilepsy-Associated Brain Tumor: a Meta-analysis.

Authors: Hang Xing; Yi Song; Zhiqi Zhang; Peter David Koch
Journal: J Mol Neurosci Date: 2021-03-31 Impact factor: 3.444